中国P站

Obesity has emerged as one of the most pressing public health challenges of the 21st century, with its prevalence rising dramatically across both developed and developing nations. Defined by the World Health Organization as an excessive accumulation of body fat that presents a risk to health, obesity is typically measured using the body mass index (BMI), where a value of 30 kg/m² or higher indicates the condition. This epidemic is not merely a matter of aesthetics or physical limitation; it is a significant driver of chronic diseases, including cardiovascular disorders such as atherosclerosis. Atherosclerosis, characterized by the buildup of plaques composed of lipids, cholesterol, and inflammatory cells within arterial walls, is a leading cause of morbidity and mortality worldwide, manifesting as heart attacks, strokes, and peripheral artery disease. While the association between obesity and atherosclerosis has long been recognized, the precise etiological links remain complex and multifaceted, involving metabolic, inflammatory, and biomechanical pathways. Understanding these connections is critical not only for advancing medical knowledge but also for designing effective interventions to curb the intertwined burdens of these conditions. This manuscript aims to explore the underlying mechanisms linking obesity to atherosclerosis, shedding light on how excess adiposity transforms into a vascular threat [1].

The growing interest in this relationship stems from the alarming statistics surrounding both conditions. Globally, over 650 million adults were classified as obese in 2016, a figure that has likely increased in the intervening years, paralleled by a rise in cardiovascular diseases, which claim approximately 17.9 million lives annually. Obesity is no longer seen as a passive state of energy imbalance but as an active contributor to systemic dysfunction. Adipose tissue, once considered a mere storage depot for fat, is now understood to be an endocrine organ that secretes bioactive molecules influencing inflammation, insulin sensitivity, and lipid metabolism all of which are implicated in atherosclerosis. Moreover, lifestyle factors such as poor diet and sedentary behavior, which fuel obesity, also exacerbate the progression of arterial plaque formation. By delving into these etiological links, this manuscript seeks to provide a comprehensive overview of how obesity sets the stage for atherosclerosis, emphasizing the interplay of biological and environmental factors [2].

Description

The etiological connections between obesity and atherosclerosis are rooted in a cascade of physiological disruptions initiated by excess adipose tissue. One of the primary mechanisms is the chronic, low-grade inflammation driven by adipocytes, the fat-storing cells within adipose tissue. In obese individuals, adipose tissue expands beyond its healthy capacity, leading to hypoxia and cell stress, which trigger the release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP). These molecules recruit immune cells, notably macrophages, into the adipose tissue and, subsequently, the arterial walls [3]. Within the arteries, macrophages engulf oxidized low-density lipoprotein (LDL) cholesterol, forming foam cells the hallmark of early atherosclerotic plaques. This inflammatory milieu not only initiates plaque formation but also perpetuates its growth, as inflamed endothelial cells lining the arteries express adhesion molecules that further attract immune cells. Thus, obesity-induced inflammation serves as a bridge connecting excess fat to vascular damage [4].

Beyond inflammation, obesity disrupts lipid metabolism in ways that directly contribute to atherosclerosis. Adipose tissue dysfunction in obese individuals leads to increased lipolysis, releasing free fatty acids (FFAs) into the bloodstream. Elevated FFAs overwhelm the liver’s capacity to process them, resulting in higher production of very-low-density lipoprotein (VLDL), which is eventually converted into LDL cholesterol—the so-called "bad cholesterol." Simultaneously, obesity is often accompanied by reduced levels of high-density lipoprotein (HDL), the "good cholesterol" that removes lipids from arterial walls. This dyslipidemia creates a lipid-rich environment conducive to plaque buildup. Moreover, FFAs contribute to insulin resistance, a common feature of obesity, which exacerbates dyslipidemia by impairing glucose and lipid homeostasis. Insulin resistance also promotes hypertension, another risk factor for atherosclerosis, as it disrupts vascular tone and increases mechanical stress on arterial walls. Together, these metabolic derangements amplify the atherogenic potential of obesity [5].

The biomechanical and hormonal effects of obesity further compound its role in atherosclerosis. Excess visceral fat, which surrounds internal organs, exerts physical pressure on the cardiovascular system, increasing cardiac workload and promoting hypertension [6]. This mechanical stress damages endothelial cells, making them more permeable to LDL cholesterol and inflammatory mediators. Additionally, adipose tissue secretes adipokines such as leptin and adiponectin, whose levels become imbalanced in obesity. Leptin, which regulates appetite, is overexpressed in obese states, contributing to endothelial dysfunction and smooth muscle cell proliferation within arteries key steps in plaque development [7]. Conversely, adiponectin, an anti-inflammatory and vasoprotective hormone, is diminished, reducing its protective effects against atherosclerosis. Oxidative stress, driven by reactive oxygen species (ROS) produced in excess fat tissue, also plays a role by oxidizing LDL and damaging vascular endothelium. These interconnected pathways illustrate how obesity acts as a multifaceted driver of atherosclerosis, extending beyond simple lipid accumulation to a systemic assault on arterial health [8].

Conclusion

The etiological links between obesity and atherosclerosis reveal a deeply intertwined relationship mediated by inflammation, metabolic dysregulation, and biomechanical stress. Obesity is not a benign condition but a dynamic state that actively remodels the body’s physiology, setting the stage for vascular disease through a network of pathways. Chronic inflammation, sparked by overburdened adipose tissue, initiates and sustains the atherosclerotic process, while dyslipidemia and insulin resistance provide the raw materials and conditions for plaque growth. Hormonal imbalances and oxidative stress further erode vascular integrity, ensuring that the effects of obesity reverberate throughout the cardiovascular system. These mechanisms underscore the urgency of addressing obesity not merely as a risk factor but as a central player in the pathogenesis of atherosclerosis. The complexity of this relationship also highlights why single-target interventions, such as cholesterol-lowering drugs alone, may fall short without addressing the upstream driver of adiposity.

From a public health perspective, these insights emphasize the need for comprehensive strategies that tackle obesity at its roots through dietary improvements, physical activity, and, where necessary, medical or surgical interventions. Preventing or reversing obesity could disrupt the cascade of events leading to atherosclerosis, potentially reducing the global burden of cardiovascular disease. Clinically, understanding these links allows for more personalized approaches to patient care, such as targeting inflammation or insulin resistance in obese individuals at risk for atherosclerosis. Future research should focus on unraveling the precise molecular interactions within these pathways, potentially identifying novel therapeutic targets. As the obesity epidemic continues to grow, so too does the imperative to bridge the gap between excess fat and arterial disease. By exploring and addressing these etiological connections, science and medicine can move closer to mitigating two of the modern era’s most formidable health challenges, offering hope for healthier, longer lives.

Acknowledgement

None

Conflict of Interest

None

References

1. Allahverdian S, Chaabane C, Boukais K, Francis GA, Bochaton-Piallat ML (2018) Cardiovasc Res 114: 540-550.

   , ,

2. Chappell J, Harman, JL, Narasimhan VM, Yu H, Foote K, et al. (2016) Circ Res 119: 1313-1323.

   , ,

3. Conklin AC, Nishi H, Schlamp F, Örd T, Õunap K, et al. (2021) Immunometabolism 3.

   , ,

4. Röhl S, Rykaczewska U, Seime T, Suur BE, Diez MG, et al. (2020) JVS Vasc Sci 1: 13-27.

   , ,

5. Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, et al. (2015) Nat Med 21: 628-637.

   , ,

6. Allahverdian S, Chehroudi AC, McManus BM, Abraham T, Francis, GA (2014) Circulation 129: 1551-1559.

   , ,

7. Vengrenyuk Y, Nishi H, Long X, Ouimet M, Savji N, et al. (2015) Arterioscler Thromb Vasc Biol 35: 535-546.

   , ,

8. Willemsen L, de Winther MP (2020) J Pathol 250: 705-714.

   , ,